On Friday, CRISPR Therapeutics AG (NASDAQ: CRSP) was 2.78% up from the session before settling in for the closing price of $51.11. A 52-week range for CRSP has been $30.04 – $78.48.
When this article was written, the company’s average yearly earnings per share was at -44.74%. With a float of $90.76 million, this company’s outstanding shares have now reached $93.87 million.
CRISPR Therapeutics AG (CRSP) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward CRISPR Therapeutics AG stocks. The insider ownership of CRISPR Therapeutics AG is 4.76%, while institutional ownership is 71.60%. The most recent insider transaction that took place on Oct 17 ’25, was worth 3,456,279. In this transaction Chief Executive Officer of this company sold 50,895 shares at a rate of $67.91, taking the stock ownership to the 254,201 shares. Before that another transaction happened on Oct 14 ’25, when Company’s Chief Executive Officer sold 4,242 for $66.60, making the entire transaction worth $282,517. This insider now owns 205,096 shares in total.
CRISPR Therapeutics AG (CRSP) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.44 earnings per share (EPS) during the time that was better than consensus figure (set at -1.19) by 0.75. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.09 per share during the current fiscal year.
CRISPR Therapeutics AG (NASDAQ: CRSP) Trading Performance Indicators
You can see what CRISPR Therapeutics AG (CRSP) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 16.22. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 130.57.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.58, a number that is poised to hit -1.18 in the next quarter and is forecasted to reach -4.13 in one year’s time.
Technical Analysis of CRISPR Therapeutics AG (CRSP)
Let’s dig in a bit further. During the last 5-days, its volume was 2.88 million. That was better than the volume of 2.57 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 12.16%.
During the past 100 days, CRISPR Therapeutics AG’s (CRSP) raw stochastic average was set at 21.08%, which indicates a significant increase from 20.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 3.55 in the past 14 days, which was higher than the 3.40 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $62.94, while its 200-day Moving Average is $49.85. However, in the short run, CRISPR Therapeutics AG’s stock first resistance to watch stands at $55.16. Second resistance stands at $57.80. The third major resistance level sits at $60.82. If the price goes on to break the first support level at $49.50, it is likely to go to the next support level at $46.48. The third support level lies at $43.84 if the price breaches the second support level.
CRISPR Therapeutics AG (NASDAQ: CRSP) Key Stats
There are 95,300K outstanding shares of the company, which has a market capitalization of 5.01 billion. As of now, sales total 37,310 K while income totals -366,250 K. Its latest quarter income was 890 K while its last quarter net income were -208,550 K.
